425: Waters & BD SpinCo Integration Update

Waters Corporation provides an update on the integration planning for its proposed business combination with BD's Biosciences and Diagnostic Solutions business, expected to close by Q1 2026.

Summary

• Waters Corporation is progressing with integration planning for its proposed business combination with Augusta SpinCo Corporation, a wholly-owned subsidiary of Becton, Dickinson and Company (BD), which includes BD's Biosciences and Diagnostic Solutions business.
• The transaction is expected to close around the end of the first quarter of calendar year 2026.
• Waters has established an Integration & Transformation Office (IO), and BD has set up a Separation Management Office (SMO) to manage the planning process.
• The combined company will be headquartered in Milford, MA, operate as Waters, and continue to trade under the ticker WAT.
• Udit Batra will continue as CEO, and Amol Chaubal will serve as SVP and Chief Financial Officer of the combined entity.
• Employees are instructed to continue operating as separate companies until the transaction closes and to direct integration-related inquiries through the IO/SMO.

Sentiment

Score: 7

Explanation: The filing conveys a generally positive and optimistic tone regarding the future of the combined company and the integration process, emphasizing innovation and value creation. However, it is balanced by a comprehensive and standard list of risks associated with such a transaction, preventing a higher score.

Positives

• The combination presents an opportunity to reimagine the future of the company.
• There is a strong focus on innovation and technology, aiming to bring together scientists and experts to accelerate market innovation.
• Management notes significant similarities in culture, focus areas, technologies, and customer bases between the combining organizations.
• Integration planning is guided by principles to capture all value creation, develop a future state enterprise inspired by innovation, leverage unique strengths, and assure minimal business disruption.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the transaction, or may require conditions, limitations, or restrictions.
• The required approval by Waters stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty exists regarding the expected financial performance of the combined company following completion of the transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delays in completion or integration, or failure to achieve expected revenue and cost synergies.
• The combined company may face difficulties in implementing its business strategy.
• Inability to retain and hire key personnel could impact the combined company.
• The occurrence of any event could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction or combined entity.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs pose risks.
• Actions by third parties, including government agencies, could affect the transaction.
• There is a risk that the anticipated tax treatment of the proposed transaction is not obtained.
• Greater than expected difficulty in separating the business of SpinCo from the other businesses of BD could occur.
• The pendency of the proposed transaction may disrupt management time from ongoing business operations.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties are possible.

Future Outlook

The combined company aims to capture all value creation, develop a future state enterprise inspired by innovation, leverage unique strengths, and ensure minimal business disruption. The transaction is expected to close around the end of the first quarter of calendar year 2026.

Management Comments

• "We have the opportunity now to reimagine the future of the company." Udit Batra, Waters President & CEO.
• "I'm really excited that the two organizations are focused on innovation and technology. We can bring together our scientists and experts to learn from each other and accelerate the innovation we bring to market." Nikos Pavlidis, Worldwide President BD Diagnostic Solutions.
• "From the moment we met, it was very obvious that there are a lot of similarities between our culture, between our focus areas, between our technologies, and the customers that we serve." Steve Conly, Worldwide President BD Biosciences.

Industry Context

This business combination aims to create a stronger entity in the life sciences and diagnostics sectors by combining Waters' existing business with BD's Biosciences and Diagnostic Solutions. This move suggests a strategic effort to enhance innovation, expand market reach, and achieve synergies in a competitive and evolving industry.

Management Changes

Corporate Governance

Legal Proceedings

• The filing identifies stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations as a potential risk that may affect the timing or occurrence of the transaction or result in significant costs.

Stakeholder Impact

• Shareholders: Waters stockholders will be asked to vote on the transaction and are urged to read SEC filings. Potential for litigation is noted as a risk.
• Employees: Will experience integration planning, potential role changes (to be mapped out), and are instructed on communication protocols during the pre-close period. Management emphasizes continued focus on current responsibilities.
• Customers: Management aims for minimal business disruption and continued support.
• Suppliers: Potential for disruption is mentioned as a risk.
• Creditors: Implied impact due to 'expected financing' and 'aggregate amount of indebtedness' for the combined company.

Next Steps

• Continue integration planning through the IO and SMO.
• Regular newsletters and updates will be provided to employees.
• Employees are to remain focused on current responsibilities and business priorities until the transaction closes.
• Waters, SpinCo, and BD intend to file relevant materials with the SEC, including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• Key leadership roles from both companies will be announced at a later date.

Key Dates

Keywords

Waters Corporation, Becton Dickinson, BD Biosciences, BD Diagnostic Solutions, Business Combination, Merger Integration, SEC Filing, WAT, SpinCo, Life Sciences, Diagnostics